Introduction
Despite numerous reports investigating the clinical significance of immune cells in the circulation and in tumor lesions, the nature of local B cell responses and functional contributions of antibodies produced in cancer are largely unexplored (1) (2) (3) (4) . Recent studies have mainly focused on the immunoregulatory roles of B cells in mouse models of cancer through mechanisms such as effector cell engagement of Fcγ receptors and production of cytokines such as TNF-α and IL-10 (5, 6).
B cells respond to a variety of local stimuli to differentiate, undergo class switching, and produce antibodies of specific classes and subclasses. Human B cells are known to produce 4 subclasses of IgG (IgG1, IgG2, IgG3, IgG4), with each subclass having different biological functions (7, 8) . These antibody types vary in their ability to activate immune system components, including the formation of the complement complex or the engagement of Fc receptors on the surface of effector cells (9) . However, whether IgG subclasses and their effector functions are of significance in cancer inflammation is relatively unknown.
IgG4 is considered a "weak" subclass due to its poor ability to bind complement and Fc receptors and to activate effector cells. IgG4 production is normally associated with prolonged exposure to antigens and has been reported to interact with antibodies of the IgG and IgE classes through their Fc domains, potentially influencing antibody-mediated functions (10, 11) . In healthy adult serum, IgG1, IgG2, IgG3, and IgG4 represent 65%, 25%, 6%, and 4% of the total IgG pool, respectively, but these proportions may be altered in certain disease contexts (8, 12) . Associations of IgG4 antibodies are reported in a range of chronic inflammatory and autoimmune conditions that feature infiltration of target organs by IgG4-expressing cells (13, 14) . Despite association with inflammatory pathologies, in allergy, elevated serum IgG4 antibody titers correlate with a reduction of allergic symptoms and successful allergen immunotherapy (15, 16) . In this context, IgG4 antibodies are thought to interfere with IgE-mediated effector cell activation. This indirectly implies a functional significance of IgG4 in modulating antigen-specific antibody-mediated effector mechanisms and in inducing clinical tolerance (17, 18) .
The relationship between IgG4 and malignancy is largely unexplored. Infiltrating IgG4 + cells in lesions of patients with extrahepatic cholangiocarcinomas and pancreatic cancers were recently reported (19, 20) , and early studies have indicated abnormalities in serum titers of IgG4 in patients with melanoma (21) . Both the presence and potential biological role of IgG4 subclass antibodies in melanoma tumor lesions remain largely unknown. Th2-mediated immune responses represent the classical hallmarks of local inflammation in solid tumors such as melanomas (22) . The immunoregulatory cytokine IL-10 has been shown to trigger "a modified Th2 response" by inducing differentiation of IgG4 + B cells and, in the presence of IL-4, to direct antibody class switching of B cells to secrete IgG4 (23, 24) .
The association between induction of IL-10 and production of IgG4 antibodies has been shown in IgG4-related diseases and also in allergic individuals undergoing allergen immunotherapy (25) . Th2-type inflammation in tumor tissues is dominated by IL-10-producing cells, such as Tregs and M2-type macrophages (26, 27) .
We therefore reasoned that these Th2-type tumor inflammatory microenvironments may favor "alternatively activated" humoral immunity and local expression of IgG4 antibodies.
In this study, we show mature B cells and IgG4 antibodies in melanoma lesions in the presence of key Th2-type cytokines that may trigger IgG4 production. Using engineered IgG1 and IgG4 antibodies of the same specificity against a tumor-associated antigen, we demonstrate the capacity of IgG4 to counteract antitumor immunity in vivo.
Results

CD22 + B cells infiltrate melanoma lesions and IgG antibodies are expressed in situ.
The presence of mature CD22 + B cells was observed in melanoma lesions by immunohistochemistry ( Figure 1A ). CD22 + cell infiltrates were found both within tumor lesions and in surrounding stroma areas rich in CD45 + cells, indicating that this population is part of the immune inflammatory infiltrate in tumors. Furthermore, CD22 + cells were also seen in close proximity to FoxP3 + Scale bar: 10 μm; original magnification, ×63. (B and E) *P < 0.01, **P < 0.01, ***P < 0.001, Mann-Whitney U test. (C and D) *P < 0.05, **P < 0.01, ***P < 0.001, Kruskal-Wallis 1-way ANOVA with Dunn's post-hoc test. Horizontal lines in box plots represent the mean, and whiskers indicate minimum and maximum values cells, which may imply associations between regulatory elements and B cells in tumors, as reported in the context of cholangiocarcinoma (19) . CD22 + cell infiltrates were found in 8 out of 9 melanoma lesions examined, and 6 of these CD22 + tumors were also positive for FoxP3 (Table 1) . Quantitative immunohistochemical evaluations also confirmed infiltration of CD22 + B cells, associated with 6 out of 6 primary and 5 out of 7 metastatic tumor lesions, while we detected sporadic CD22 + infiltrates in 2 out of 8 healthy skin specimens ( Figure 1B and Supplemental Figure 1 , left panel; supplemental material available online with this article; doi:10.1172/JCI65579DS1). Primary and metastatic melanoma tumors had ≥7 CD22 + B cells per high-powered microscope field, compared with very low or absent CD22 + B cell infiltration in healthy skin (P < 0.05 and P < 0.001, respectively; Figure 1B) .
The presence of CD22 + B cells in melanoma lesions was also confirmed by quantitative RT-PCR analyses. CD22 mRNA expression was determined in healthy skin (n = 9), primary melanoma lesions (n = 10), and melanoma skin metastases (n = 10) ( Figure  1C ). We detected low to no expression of CD22 mRNA in healthy skin samples and significantly elevated levels in primary and metastatic melanoma skin lesions (P < 0.01 and P < 0.001, respectively), suggesting recruitment of mature B cells to tumors ( Figure 1C) . Levels of mature IgG mRNA were elevated in metastatic melanoma lesions (n = 10) compared with those in both primary melanomas (n = 10) (P < 0.05) and healthy skin samples (n = 9) (P < 0.001), in which there was little to no expression ( Figure 1D and Table 2 ). When we analyzed IgG4 expression by disease stage, we found significantly higher expression of IgG mRNA in lesions from patients with stage IV disease (n = 6) compared with expression in lesions from patients at stages I-III (n = 14) ( Figure 1E ). Local expression of CD22 + IgG + B cell infiltrates was detected in melanoma lesions, as determined by dual-color immunofluorescence ( Figure  1F ). These data confirm that mature antibody-expressing B cells infiltrate melanoma lesions and that IgG antibodies are expressed locally in metastatic melanoma.
Tumor-associated B cells are polarized to produce IgG4 antibodies in Th2-biased inflammatory melanoma microenvironments. To examine the proportions of IgG subclasses produced in melanoma, B cells from melanoma skin lesions (n = 2, stages III and IV), patient lymph nodes (n = 3, stage III), patient blood (n = 6, stages III and IV), and healthy volunteer blood (n = 4) were cultured ex vivo (Tables 2  and 3 and Supplemental Table 1 ). IgG subclass titers (IgG1, IgG2, IgG3, IgG4) in culture supernatants were then measured by ELISA. Proportional IgG subclass expression and IgG4/IgG total ratios from healthy volunteer peripheral blood B cells (IgG1: 79.5% ± 8.5%; IgG2: 14.3% ± 7.9%; IgG3: 4.3% ± 1.5%; IgG4: 1.5% ± 1%), patient peripheral blood B cells (IgG1: 76.4% ± 14.3%; IgG2: 15.8% ± 10.2%; IgG3: 4.1% ± 3.2%; IgG4: 3.9% ± 2.2%), and B cells from patient lymph nodes (IgG1: 83.2% ± 3.6%; IgG2: 6.5% ± 0.5%; IgG3: 3.3% ± 1.0%; IgG4: 7.0% ± 2.1%) were consistent with those commonly detected in human sera (IgG4/IgG total ratio range: 0.01-0.083, each condition tested in triplicate) (Figure 2A and ref. 12). However, B cells derived from metastatic melanoma lesions exhibited higher proportional IgG4 subclass production (IgG4/ IgG total ratio range: 0.209-0.334) (IgG1: 43.2% ± 1.7%; IgG2: 4.1% ± 1.4%; IgG3: 24.8% ± 3.5%; IgG4: 27.5% ± 5.3%) (Figure 2A) .
Using immunohistochemical evaluations, we also detected substantial levels of IgG4-immunopositive cells infiltrating tumor areas in primary and metastatic melanoma lesions, while IgG4 + cells were rarely observed in healthy skin ( Figure 2B , left, and Supplemental Figure 1 , right panels). These observations were confirmed with quantitative assessments of sections, which showed IgG4 positivity in 9 out of 12 melanomas and sporadic expression in 2 out of 10 healthy skin specimens (P < 0.001; Figure 2B , right). Furthermore, immunohistochemical evaluations of IgG4 + infiltrates were examined in relation to clinical parameters for a cohort of 9 patients. Although these observations are limited by the small number of patients, it is noteworthy that 3 patients who are deceased demonstrated IgG4 positivity in the lesions tested ( Table 1) . Expression of IgG4 was also confirmed by RT-PCR sequence alignments of patient specimens (representative clone in Supplemental Figure 2 ). These data suggest that IgG4 production occurs in situ in the melanoma microenvironment.
We then asked whether IgG4 antibodies in the tumor microenvironment and in patient circulation may recognize tumor cells. For this, we examined the reactivities against tumor cells of IgG1 and IgG4 antibodies produced by B cells derived from patient blood (n = 2, patients in stage III and IV), cutaneous metastases (n = 3, 2 patients in stage III and 1 patient in stage IV), and a lymph node metastasis (n = 1, a patient in stage III) and cultured ex vivo for 5 days. Tumor cell reactivity evaluations were conducted using a previously described cell-based ELISA (28). We found detectable levels of IgG4 reactivity against A375 metastatic melanoma cells, above background set by human IgG4 antibody controls, in Evaluation criteria were as follows: -, 0% infiltration; +/-, <25% infiltration; +, >25% < 50% infiltration; ++, >50% infiltration; +++, >75% infiltration. See also Figures 1 and 2 . n = 9. NA, not available.
1 blood sample and 1 cutaneous metastasis ( Figure 2C ). In the same specimens, we found no equivalent detectable reactivity of IgG1 antibodies against these tumor cells. In contrast, we detected IgG1 antibody reactivity to melanoma cells in the lymph node sample without detectable equivalent IgG4 reactivity. Additionally, using 2-color immunofluorescence on a cutaneous melanoma lesion, we demonstrated colocalization of IgG4 with the melanoma-associated antigen S100, further supporting the presence of tumor reactive IgG4 antibodies in situ ( Figure 2D ). These experiments, together with detected IgG4 expression in melanoma lesions by RT-PCR analysis (Supplemental Figure 2) , suggest that tumorreactive antibodies of the IgG4 subclass are expressed by patient B cells situated in both melanoma lesions and the circulation. We reasoned that the polarization of IgG4 in situ may be influenced by local factors, such as production of IL-10 in combination with IL-4, which is known to induce differentiation of IgG4 + B cells, drive class switching, and to maintain polarization of humoral immune responses in favor of IgG4 (29) . Accordingly, we found significantly elevated mRNA expression of the Th2 cytokines IL4 and IL10 and of the inflammatory cytokine IFNG, reported to be involved in tumorigenesis, by quantitative RT-PCR in both primary (n = 10) and metastatic (n = 10) melanoma skin specimens when compared with healthy skin samples (n = 9) (P < 0.05; Figure 2E and ref. 30 ). Secretion of these cytokines was also confirmed in ex vivo cultures of tumor lesions ( Figure 2F ). These findings indicate a potential association of Th2-biased local expression of IL-10 and IL-4 with IgG4 production at inflammatory tumor sites. 9.2% ± 1.3%; IgG4: 6.7% ± 1.2%) (n = 9, Figure 3A , left). When we compared IgG4 polarization of B cells plus PBMCs in the absence or presence of melanocytes (IgG1: 51.9% ± 2.9%; IgG2: 21.5% ± 4.2%; IgG3: 14.0% ± 1.5%; IgG4: 12.6% ± 2.8%), we observed a small, but not statistically significant, difference in IgG4/IgG total ratios with the addition of melanocytes, indicating that IgG4 polarization may be partly due to an allogeneic HLA mismatch effect in these assays. We demonstrated significant changes in IgG4 polarization (higher IgG4/IgG total ratios) when comparing B cells, PBMCs, and melanocytes with samples of B cells, PBMCs, and melanoma cells (P < 0.05). The overall titers of IgG antibodies produced in the presence or absence of melanoma cells in these assays were comparable ( Figure 3A , right). We next asked whether ex vivo production of IgG4 in the presence of melanoma cells is associated with Th2-biased inflammatory cytokines. Consistent with our findings in metastatic melanoma lesions, ex vivo stimulation of B cells with metastatic melanoma cells triggered enhanced IL-4 and IL-10 levels, as compared with B cell cultures in the absence of melanoma cells (P < 0.01 and P < 0.05, respectively) ( Figure 3B ). We also detected increased titers of VEGF, IL-6, and MCP-1, but not IFN-γ, in cocultures with melanoma cells (Supplemental Figure 3A) . In contrast, when we compared IL-4 and IL-10 titers in cultures of B cells and PBMCs in the presence or absence of melanocytes, we did not observe any significant increases ( Figure 3C ). These findings indicate that melanoma cells drive Th2-biased inflammatory environments favoring increased IgG4/IgG total production ratios.
To further investigate the origin of Th2 cytokine production, we harvested A375 melanoma cells before and after coculture assays by flow cytometric cell sorting (strategy for flow cytometric sorting shown in Supplemental Figure 3B ). We demonstrated increased expression of IL-10 by these cells following coculture with B cells and PBMCs. Message for IL-4 was not detected, and VEGF mRNA was present but was not upregulated following coculture ( Figure 3D ). When cultured alone under normal culture conditions, melanoma cells did not express or secrete IL-4, but the cells secreted detectable levels of IL-10 ( Figure 3E ). These assays point at enhanced expression of IL-10 by melanoma cells in these coculture assays. Neither B cells nor tumor cells expressed IL-4 message under these culture conditions, and therefore, IL-4 may be contributed by another cell type in PBMCs (Supplemental Figure 3C) or possibly stromal cells in the tumor microenvironment.
Having shown that tumor cells produce IL-10 in culture, next we investigated the cytokines produced by sorted B cells in these culture conditions (strategy for flow cytometric sorting shown in Supplemental Figure 3D ). B cells in coculture experiments upregulated VEGF expression, while expression of IL-10 by these cells was detected but not upregulated following coculture with tumor cells ( Figure 3F ). These experiments suggest that B cells may contribute to polarized humoral immunity by enhancing production of VEGF.
IgG4 subclass antibodies lack antitumoral effector functions and block IgG1-mediated tumor cell killing by patient monocytes. To explore potential mechanisms by which IgG4 may impact on antitumoral responses, we engineered 2 antibodies, with IgG1 and IgG4 Fc regions, that share identical variable regions recognizing the melanoma-associated antigen CSPG4. With these, we attempted to mimic a clinically relevant situation, in which IgG1 and IgG4 were found alone or together in the presence of tumor antigen-expressing cancer cells and FcγR-expressing immune effector cells, such as patient monocytes/macrophages (5, 19) . Both antibodies bound to FcγR-expressing U937 monocytes, to patient monocytes (Figure 4 , A-C), and to a panel of melanoma cells ( Figure 4D ).
First, we examined the ability of each antibody to activate patient-derived monocytes to kill tumor cells in vitro. Patient monocytes incubated with anti-CSPG4 IgG4 and A375 melanoma cells mediated nonsignificant tumor cell killing compared with a nonspecific IgG4 (antibody clone SP211-IgG4) after 3 hours (n = 6). In contrast, the corresponding anti-CSPG4 IgG1 of the same specificity triggered statistically significant increases in phagocytosis (antibody-dependent cellular phagocytosis [ADCP]) (21.1% ± 2.5%) of melanoma tumor cells by monocytes compared with anti-CSPG4 IgG4 (3.2% ± 0.3%) and controls (2.6% ± 0.1%) (P < 0.001; Figure 5 , A and B). Consistent with reduced IgG4 antitumor activity, we detected lower levels of IFN-γ (P < 0.01), IL-1β (P < 0.01), and TNF-α (P < 0.05) in supernatants from cultures treated with anti-CSPG4 IgG4 compared with those treated with anti-CSPG4 IgG1 (n = 6) ( Figure 5C ).
When anti-CSPG4 IgG1 and anti-CSPG4 IgG4 were combined with patient-derived monocytes and melanoma cells, the tumoricidal capacity of anti-CSPG4 IgG1, previously observed in the antibody-dependent cellular cytotoxicity/ADCP (ADCC/ADCP) assays, was significantly reduced in the presence of anti-CSPG4 IgG4 (P < 0.001, Figure 5D ). This suggested that anti-CSPG4 IgG4 is not only incapable of triggering effector cell-mediated tumor killing but may additionally suppress tumor cell killing capacity of tumor-specific IgG1. To evaluate whether specificity for the tumor antigen was necessary for an IgG4 antibody to block IgG1 effector cell functions against tumor cells, we performed ADCC/ ADCP (cytotoxicity/phagocytosis) assays, incubating tumor cells and patient-derived monocytes with anti-CSPG4 IgG1 in combination with a human IgG4 antibody of irrelevant specificity. Nonspecific IgG4 partly hindered tumor-specific IgG1 tumor cell killing (P < 0.001; Figure 5E ), suggesting that tumor cell specificity may only be partly responsible for the antibody modulatory properties of IgG4. These data are in line with known properties of IgG4 interactions with Fc regions of immunoglobulins, and they are also consistent with reports that only a small fraction of IgG4 antibodies are allergen specific in allergic subjects following immunotherapy (31) . In summary, IgG4 antibodies lack antitumoral effector functions and impair IgG1-mediated tumor cell killing by patient monocytes. In order to investigate which FcγR is predominantly responsible for the induction of tumor cell killing via IgG1, we conducted tumor killing assays during which individual FcγR families were blocked with antibodies described in the literature to have an inhibitory capacity for these specific receptor families. We demonstrate that, in this experimental system, blockade of FcγRI, but not of the other 2 receptor families, was responsible for the IgG1-mediated tumor cell killing ( Figure 6B ). We confirmed the widespread distribution of FcγRI along with the other 2 FcγRs (FcγRII and FcγRIII) in melanoma lesions (1 representative of 4 patient specimens shown in Supplemental Figure 4) . Since FcγRs such as FcγRIIb are known to play immunomodulatory roles, we investigated whether specific inhibition of IgG binding to each of these receptor families had any bearing on the killing inhibition mediated by IgG4. In these experiments, we found that inhibition of CD32 is not involved in IgG1 blocking by IgG4 ( Figure 6C) .
Next, at different time points during in vitro tumor cell killing assays, we harvested monocytes by flow cytometric sorting and assessed phosphorylation of downstream signaling events triggered through engagement of FcγR engagement and activation (32) . We observed increased phosphorylation of known members of the FcγR activatory signaling cascades (Src, MEK, and AKT) in the presence of IgG1 compared with the presence of both IgG1 and IgG4 antibodies (33) . On the contrary, there were no differences in the levels of phosphorylated SHIP1 in relation to CSPG4 IgG1 or in relation to coincubation with IgG1 and IgG4 antibodies together at any of the time points tested (Figure 6D ). These data suggest that inhibition of IgG1-mediated tumor cell killing by IgG4 is attributed to lack of effector cell activation rather than induction of inhibitory signals via FcγRs such as FcγRIIb. We conclude that in this experimental system IgG4 functions by competing with IgG1 for FcγRI binding and therefore blocking the activatory cascades through reduced phosphorylation of Src, MEK, and AKT.
IgG4 impairs antitumor immunity in a human melanoma xenograft model. Next, we compared the efficacies of anti-CSPG4 IgG1 and IgG4 in vivo in a subcutaneous human melanoma xenograft mouse model engrafted with human immune effector cells (Supplemental Figure 5 and ref. 34 ). Intravenous treatment with anti-CSPG4 IgG1 (3 × 10 mg/kg weekly doses) significantly reduced tumor size compared with treatments with nonspecific mAb or vehicle controls (n = 6, P < 0.05; Figure 7A ). However, tumor size in anti-CSPG4 IgG4-treated mice increased in line with that in controls, suggesting that IgG4 was significantly less effective than IgG1 at restricting tumor growth in vivo (P < 0.001). Furthermore, when anti-CSPG4 IgG1 and IgG4 were administered together, tumors grew similarly to vehicle-treated controls (n = 6, P < 0.001 for IgG1/ IgG4 combinations compared with IgG1 treatment alone; Figure  7A ), indicating that anti-CSPG4 IgG4 might counteract IgG1 antitumor functions in vivo.
To ascertain that impaired antitumoral functions of anti-CSPG4 IgG4 were not due to inability of IgG4 to localize in CSPG4-expressing tumors in the mice, 111 In radio-labeled anti-CSPG4 IgG4 biodistribution was monitored by PET/SPECT imaging of human xenografts (n = 3). Accumulation in tumors was observed within 24 hours following antibody treatment (Figure 7B) . Furthermore, we observed that subcutaneous human melanoma xenografts from mice treated with anti-CSPG4 IgG1 attracted higher levels of human CD68 + cells (macrophages) compared with mice treated with IgG4 or combinations of IgG1 and IgG4 antibodies ( Figure 7 , C and D). These findings indicate that macrophages may be recruited and potentially play a role in restricting tumor growth when engaged by CSPG4 IgG1 in situ.
Serum IgG4 antibodies may be predictive of clinical outcomes in melanoma.
Having investigated the immunomodulatory potential of IgG4 in melanoma in vitro and in vivo, we then evaluated whether the presence of IgG4 in patient circulation could be used as a possible biomarker. We performed IgG1-IgG4 subclass Luminex bead array assays using sera from 33 patients with stage III and IV melanoma ( Figure 8 and Table 4 ). Spearman correlation analyses were performed to examine any significance among IgG subclass titers in sera in relation to patient survival. We demonstrated a negative correlation only between IgG4 serum titers and patient survival (r = -0.31, P < 0.05), while no significant correlations were found in relation to the other IgG subclasses ( Figure 8A ).
Normal IgG4/IgG total ratios in human sera have been reported around 0.025 (35) . In this study, we confirmed this ( Figure 2A ) and additionally found that IgG4/IgG total ratios in patient sera had a median of 0.034 (95% CI of mean, 0.024-0.044). We therefore reasoned that serum IgG4/IgG total ratios above the 75% percentile (IgG4/IgG total = 0.04) may be considered high in patient sera (Supplemental Figure 6 ). To gain an insight into the significance of IgG4/IgG total ratios in patient sera, we analyzed cumulative survival on a Kaplan-Meier survival plot in our 33 patient cohort. We found that patients with higher serum IgG4/IgG total ratios (>0.04, n = 13) had significantly lower survival rates (median survival 8 months; hazard ratio, 0.19; 95% CI, 0.0635-0.5685) compared with patients whose IgG4/IgG total serum ratios were <0.04 (n = 20) (P < 0.01) ( Figure 8B ).
Overall, we have shown that IgG4 subclass antibodies are present in tumor lesions and that they are inefficient in restricting melanoma tumor cell growth. In addition, IgG4 suppressed IgG1-mediated melanoma cell killing in vitro and in a clinically relevant humanized mouse engrafted with human melanoma. When examined in relation to clinical outcomes, data presented here suggest that IgG4 is associated with reduced survival and may be evaluated as a prognostic biomarker in melanoma. 
Discussion
Despite the fact that B lymphocytes constitute important sentinels of adaptive immunity and the antibody-mediated immune response, the mechanisms by which they participate in tumor immunity remain only partially understood (2-4, 36-39). We described a hitherto undiscovered aspect of local humoral immunity in melanoma, characterized by B cell infiltration and local expression of IgG4 antibodies, in the context of prominent expression of IgG4 polarizing cytokines IL-10, IL-4, and VEGF. We demonstrated that, in the presence of melanoma cells, production of these cytokines is enhanced and B cells are polarized to produce IgG4 ex vivo. Importantly, we showed that IgG4 antagonizes IgG1-mediated human anti-melanoma immunity in vitro and in vivo and that IgG4 blockade is mediated through competition with IgG1 for FcγR binding and therefore inhibits downstream signaling activation of effector cells (i.e., monocytes).
Previous studies have reported the presence of CD20 + cells in melanoma lesions (2, 3), but this pan-B cell marker is also expressed by melanoma stem cells (40, 41) . We selected the B cell marker CD22 to differentiate B cells from melanoma stem cells and to study mature B cells that may express class-switched antibodies. We detected CD22 at the mRNA and protein levels in melanoma lesions but at very low levels in normal skin (Figure 1 ). These cells were observed within tumor lesions and also surrounding stroma areas rich in CD45 + cells, indicating that B cells form part of the immune inflammatory infiltrate; however, the significance of CD22 + B cell infiltrates in cancer remains unclear. B cell and plasma cell (CD138) infiltration in melanoma have been associated with favorable clinical outcomes, and lymphoid structures containing B cells (CD20) and also plasma cells (CD138) were recently reported (4, 42) . Other reports highlight immunomodulatory roles for B cells in cancer, suggesting that their contribution may reflect a balance between effective immunity and tumorinduced inflammation (20, 43) .
The presence of mature IgG mRNA in metastatic melanoma lesions and CD22 + IgG + and IgG4 + cells infiltrating tumor cell areas suggest that B cells may participate in local tumor surveillance through production of antibodies. This study demonstrates the expression of IgG antibodies in situ rather than being sequestered or diffused into tumors from the circulation. This was shown by the detection of mature IgG mRNA, IgG4 clone expression, and IgG4 + infiltrates in melanoma lesions as well as by the production of tumor-reactive IgG4 antibodies by tumor-resident B cells (Figure 2 ). Recent findings implicate increased IgG4 serum titers and IgG4 + tissue infiltrates in a range of inflammatory conditions triggered by chronic exposure to nonmicrobial antigens (14, 18, 31) . Our findings demonstrating increased expression of IgG, the presence of IgG4 + infiltrates in tumors, and tumor-reactive B cells in lesions are consistent with exposure to tumor antigens, as this might allow for antibody class switch recombination (44) .
We found a striking polarization in IgG subclass distribution produced by tumor-derived B cells in favor of IgG4 (Figure 2) . We directly showed a role for tumor cells in influencing IgG4 production by B cells (Figure 3) . Furthermore, ex vivo stimulation of human B cells with melanoma cells also resulted in a similar proportional increase in IgG4/IgG total ratios compared with unstimulated B cells, and we demonstrated that melanoma tumor cells, but not normal human melanocytes, are capable of polarizing B cell responses in favor of IgG4 production. In melanoma tumor lesions, these increased IgG4/IgG total ratios were accompanied by expression of Th2-biased inflammatory cytokines known to drive production of IgG4 by B cells. Tumors circumvent immunemediated clearance by triggering inflammatory cells with immunoregulatory properties and immunosuppressive mediators (e.g., IL-10, VEGF, TGF-β) in situ (34, 45, 46) . The immunoregulatory cytokine, IL-10, can direct "a modified Th2 response" favoring B cell production of IgG4 (23, 25, 47) . In support of this, we have found induction of increased IL-10 production by tumor cells cultured with B cells ex vivo. IL-10 has been implicated in modified Th2 responses in the context of IgG4-related diseases (48, 49) . Although IgE and IgG4 are triggered by similar Th2-biased signals, IL-10 is thought to divert a classical Th2-type immunity, bypassing IL-4-induced IgE responses in favor of IgG4 (23, 29) . Classically, high IgG4/IgG total ratios are considered a natural effort by the immune system to contain immune activation. These alterations, however, have also been documented in individuals chronically exposed to occupational or environmental antigens and are not normally accompanied by development of IgE (50, 51) . Consistent with this, we detected IgE mRNA in only 2 out of 10 patient lesions that we examined (data not shown), which also points to the involvement of altered Th2 responses in tumor microenvironments (52) .
As reported by others in the context of IgG4-related diseases, we detected local expression of tissue-resident IgG4 together with enhanced expression of IL-10 and IL-4 cytokines in tumors (Figure 3  and ref. 49) . We also demonstrated that tumor cells are capable of stimulating such modified Th2 responses, featuring production of IL-10 and IL-4 and secretion of IgG4 by B cells. Also consistent with a tumor-associated inflammatory environment, VEGF, known to polarize Th2-biased cytokine production by PBMCs through induction of IL-10-secreting cells such as Tregs (53), along with well-described tumor-induced inflammatory mediators IL-6 and MCP-1 (53) (54) (55) (56) , was found at significantly increased levels (P < 0.001; Supplemental Figure 3A Figure 8 . n = 33.
antigen recognition, and, in support of this, we found tumor-reactive IgG4 antibodies associated with melanoma lesions. Second, IgG4 could bind to Fcγ receptors, preventing IgG1 interactions on the surface of effector cells. The implications of the latter mechanism would be that IgG4 of any specificity could neutralize IgG1-FcR-mediated effector functions against tumors through engagement of the main Fcγ receptor families (58) . In agreement with this possibility, a nonspecific IgG4 also blocked IgG1-mediated tumor cell ADCP by patient monocytes almost as effectively as the tumor antigen-specific IgG4 ( Figure 5 ). This suggested that antigen specificity may only partly account for the IgG4 antibody-neutralizing properties (31, 59, 60) . Furthermore, here we demonstrated that tumor antigen-specific IgG4 inhibited IgG1-dependent tumor cell killing by blocking activatory signal cascades associated with FcγRI effector mechanisms, which would normally lead to functions such as ADCP ( Figure 6 ). One can therefore envisage that if IgG4 antibodies are abundant in tumor microenvironments, their proximity to tumor cells may not only inhibit the effector functions of naturally expressed antibodies, but IgG4 could also impair therapeutic antibody effector functions in situ by one or more mechanisms, as has already been reported following antibody treatments for rheumatoid arthritis (61, 62) . Our findings are also consistent with similar reported functional roles of IgG4 in blocking immune responses in atopic individuals receiving allergen immunotherapy (18, 31) . While these effects signal the relief of symptoms and successful allergen immunotherapy, the presence of IgG4 in tumor microenvironments and its antibody-neutralizing functions may contribute to evasion of the humoral immune response to cancer.
Further supporting the potential significance of IgG4 in melanoma growth are our findings that elevated levels of IgG4 in patient sible that IL-4 production may be contributed by other stromal or immune cells in tumor microenvironments. Our findings therefore identify melanoma tumor cells as potential inducers of IgG4 in tumor microenvironments via B cell-produced VEGF, triggering enhanced IL-10 production by tumor cells.
Insights into how IgG4 antibodies contribute to immune homeostasis and to different disease pathologies are starting to emerge. IgG4 is considered a "nonactivating" subclass associated with chronic inflammation and limited immune activating functions (57) . Links between IgG4 and tissue inflammation (14) , in the context of well-characterized inflammatory mechanisms at play in tumors, raise the possibility of a key role for this antibody subclass in tumor inflammation. In support of this concept, we have shown the local presence of IgG4 antibodies in melanoma and their contributions to tumor inflammatory responses. In addition, we found that tumor antigen-specific IgG1, but not the corresponding IgG4, could activate patient-derived monocytes to kill tumor cells in vitro ( Figure 5 ). These findings were confirmed by in vivo experiments, since tumor antigen-specific IgG4 was unable to restrict tumor growth, despite accumulating in tumor lesions (Figure 7) . Polarizing humoral responses in favor of IgG subclasses with low or no potency in activating effector cells against tumors may therefore represent a mechanism of tumor escape.
Another potential mechanism relates to IgG4 interactions with other IgG antibodies and its capacity to impede IgG functions that would otherwise activate effector cells to eradicate tumors. We observed that a tumor antigen-specific IgG4 antibody hindered the ability of the corresponding IgG1 to induce ADCP of tumor cells by patient monocytes. This may be the outcome of one or more potential scenarios. First, IgG4 may compete with IgG1 for tumor sera are associated with poorer survival (Figure 8 ). Data presented here mandate a closer examination of IgG4 antibodies but also of IgG3 antibodies, which are also proportionally elevated in tumors and possess lower effector cell activatory properties compared with IgG1 antibodies (63) , as potentially useful biomarkers in tumor lesions and/or in the circulation. Additionally, data demonstrating VEGF and IgG4 production by B cells in the presence of tumor cells imply that B cells may be "reeducated" through cross-talk with tumor cells and highlight the need to further dissect the mechanisms by which tumors escape humoral immune responses.
In conclusion, we present the first evidence of local IgG4 expression in melanoma, associated with the IgG4-polarizing cytokines IL-10, VEGF, and IL-4. Our data suggest that IgG4 antibodies triggered in the presence of tumor cells participate in local inflammation and may represent one regulatory mechanism by which tumors evade immune attack. Studies in larger cohorts of patients are required to elucidate associations of IgG4 with immunological, molecular, and clinical parameters and patient responses to treatments, paving the way for biomarker development and design of personalized medicine approaches. Future strategies to counteract IgG4 immunoregulatory pathways or to design antibody treatments and derivatives less prone to IgG4 blockade will be of potential therapeutic value.
Methods
Patient data and specimen collection. Melanoma tumor skin lesions, lymph nodes, and blood were collected from a total of 57 patients diagnosed with stage I-IV malignant melanoma (Tables 1-3 and Supplemental Table 1 ). Patients were staged and classified according to the American Joint Committee on Cancer Melanoma Staging and Classification criteria (64) . Samples were used fresh, or placed in OCT for cryosectioning or in RNAlater solution (Life Technologies) and stored at -70°C for subsequent RNA extraction, or fixed in formal saline and embedded in paraffin. Discarded human skin samples were obtained from 18 volunteers undergoing routine plastic surgery. Human peripheral blood lymphocytes (PBLs) and B cells were isolated from a cohort of 8 healthy volunteers. Human samples were collected with informed written consent, in accordance with the Helsinki Declaration, and study design was approved by the Guy's Research Ethics Committee, Guy's and St. Thomas' NHS Foundation Trust.
Human cell isolation and ex vivo stimulation assays. Peripheral blood B cells from patients with melanoma and healthy volunteers were isolated using the B cell enrichment cocktail (Stemcell Technologies) and cultured at a density of 500 cells per well (in 96-well plates) in combination with (3,010 cGy) irradiated autologous PBMCs, Epstein-Barr virus, and the TLR9 agonist CpG 2006, as previously described (28) . Single cell suspensions were derived from patient tissues (lymph nodes or melanoma skin lesions) using a Gentle MACs Tissue Dissociator (Miltenyi) and filtered through a 100-μm strainer. In ex vivo stimulation experiments, human peripheral blood B cells were cocultured for 5 days together with irradiated PBMCs and tumor cells at 1:5:10 ratios in RPMI 1640 medium, 10% FCS, 2 mM l-glutamine, penicillin (5,000 U/ml), and streptomycin (100 μg/ml) (all Life Technologies) (65) . Primary human monocytes from patients with melanoma were obtained using the monocyte enrichment cocktail (Stemcell Technologies) according to the manufacturer's instructions (66) . Luminex bead array analysis. Luminex Bead Array Assay Kits, Milliplex for cytokines (Millipore) or Bioplex for IgG subclasses (Bio-Rad), were used according to the manufactures instructions, and data were acquired and analyzed using a FlexMap3 (Luminex Cooperation) or Bio-Plex200 (Luminex Cooperation), respectively.
Production of human anti-CSPG4 antibodies. The cDNA of the heavy and light chain variable regions directed against the human CSPG4, a cell surface antigen expressed by >80% of malignant melanomas, were derived from previously published variable region sequences of the murine mAb 225.28S (68) (69) (70) , and antibodies were subsequently cloned and produced in an method analogous to that previously described (71) .
Flow cytometric and ImageStream evaluations of antibody binding. For assessment of antibody binding to CSPG4 on a panel of human melanoma cell lines (A375, A-2058, G-361, WM-115, SK-MEL-28, Malme-3M), primary human melanocytes, U937 monocytes, or human primary monocytes, cells were incubated with 10 μg/ml mAbs for 30 minutes at 4°C, followed by 2 washes in PBS with 5% normal goat serum (FACS buffer). Cells were then treated with goat anti-human IgG (Fab′)2-FITC antibody or goat anti-human IgG1-PE (10 μg/ml) (Jackson ImmunoResearch) for 30 minutes at 4°C and washed in FACS buffer prior to acquisition and analysis on a FACSCanto flow cytometer (BD Biosciences) or ImageStreamX (Amnis Corporation). For ImageStreamX, quantitative analyses are based on the acquisition of 20,000 cell events, and MFIs were measured and calculated using an object mask to detect surface staining only.
Cytotoxicity/phagocytosis (ADCC/ADCP) assays. Antibody-dependent cellmediated killing of CSPG4-expressing cells by anti-CSPG4 antibodies was quantified by a 3-color flow cytometric ADCC/ADCP assay, as previously described (72) . Briefly, A375 melanoma cells were stained 24 hours prior to assays with 5.0 μM CFSE (5-[and 6-] carboxyfluorescein diacetate succinimidyl ester, Life Technologies) in PBS for 10 minutes at 37°C; washed in DMEM medium, 10% FCS, 2 mM l-glutamine; and returned to standard culture conditions. The following day, CFSE-labeled tumor cells were washed and then mixed with human monocytes at an E/T cell ratio of 2:1, with or without (5 μg/ml) antibodies, followed by a 3 hours incubation at 37°C. Cells were then washed in PBS with 2% normal goat serum (FACS buffer), incubated for 30 minutes with a mouse anti-human CD89 PE (BD Biosciences), washed again in FACS buffer, and resuspended in PBS supplemented with DAPI (Life Technologies). All assay conditions were tested in triplicates and replicated in 6 independent experiments using peripheral blood monocytes derived from 6 patients with stage II melanoma.
Assessments of receptor function were conducted using blocking antibodies: mouse anti-human FcγRI (Biolegend); mouse anti-human FcγRII (Abcam); and mouse anti-human FcγRIII (Abcam), which have been previously described to block the antibody Fc-mediated functions of different FcγR family members (73) (74) (75) . Blocking experiments with specific or nonspecific IgG4 antibodies were conducted using a 3:1 (IgG4/IgG1) ratio.
Samples were acquired immediately using a FACSCanto flow cytometer (BD Biosciences). For event acquisition and analysis, CFSE-labeled tumor cells were detected in FITC (530/30-nm band-pass filter and a 502-nm long-pass filter), CD89-PE-labeled primary monocytes were detected in PE (585/42-nm band-pass filter and a 556-nm long-pass filter), and DAPI + dead cells were detected in Pacific Blue (345/20-nm band-pass filter) channels, while control samples were set for compensation adjustments between CFSE and PE. Two dual-color flow cytometric dot plots were generated to calculate ADCC and ADCP, as previously described (66, 72, 76) .
Assessments of antibodies in a subcutaneous human melanoma model in NOD/ SCID/Il2rg -/-mice engrafted with human immune cells. Male and female NOD/ SCID/Il2rg -/-mice (NOD.cg-Prkdc SCID Il2rg tm1Wjl /SzJ [NSG]; The Jackson Laboratory) were used at between 6 and 10 weeks of age. Mice were maintained under specific pathogen-free conditions and handled in accor-dance with the Institutional Committees on Animal Welfare of the UK Home Office (The Home Office Animals Scientific Procedures Act, 1986). NSG mice were injected subcutaneously with 5 × 10 5 A375 melanoma cells in 150 μl PBS. On day 5, mice received intravenous injections of 10 × 10 6 human PBLs (derived from whole human blood by lysis of red blood cells) and 10 mg/kg of antibody. Subsequent injections of antibody treatments were given 3 times on days 12, 18, and 25 at doses of 10 mg/kg each in 150 μl PBS. A control group was treated with 10 × 10 6 human PBLs on day 5 and injected with 150 μl of PBS on days 12, 18, and 25. Tumor growth was monitored and measured using calipers. Tumor size (mm 3 ) was calculated using the following formula: mm 3 Experiments were terminated once the first animal was measured with a subcutaneous tumor size no greater than 750 mm 3 . Spleen engraftment of 40%-70% human CD45 + cells was confirmed by flow cytometry for all experiments (Supplemental Figure 5) .
NanoSPECT/CT imaging of anti-CSPG4 antibody in vivo. NSG mice were injected subcutaneously with 5 × 10 5 A375 tumor cells on day 0. On day 5 mice were injected intravenously with 10 × 10 6 human PBLs. Spleen engraftment was analyzed as above (Supplemental Figure 5) . Anti-CSPG4 IgG4 (7 mg) was conjugated with the bifunctional chelator CHX-A"-DTPA prior to experiments, and on day 24, the antibody was radiolabeled with 20 MBq of Indium-111 (St. Thomas' and Guy's Trust, KCL, London, Radiopharmacy) and administered intravenously at 10 mg/kg as above. Images were captured under anesthesia after 20 minutes, 8 hours, and 24 hours using a NanoSPECT/CT preclinical imager (Bioscan) equipped with a multipinhole (9 pinholes; aperture 1.0 mm) collimator and reconstructed using the Invivoscope software (Bioscan).
Statistics. Comparative quantitative PCR analyses in human skin specimens were conducted using a Kruskal-Wallis analysis with a Dunn post-hoc test. Comparative analyses of immunohistochemical staining were performed using a Mann-Whitney U test. One-way ANOVA with Bonferroni post-hoc test was used to compare ADCC/ADCP of tumor cells by human monocytes, triggered by antibodies. Two-way ANOVA with Bonferroni post-hoc test was used to compare restriction of tumor cell growth in vivo. For correlation and patient survival analyses, Spearman and Mantel-Cox analyses were applied. All statistical analyses were performed using GraphPad Prism software (version 5.03, GraphPad). Error bars in all in vitro figures represent SD. Error bars in all in vivo figures and histological analyses represent SEM.
